Mavyret is a prescription medication used to treat chronic hepatitis C virus (HCV) infection [1]. The typical dosage for Mavyret depends on the specific HCV genotype and whether the patient has previously been treated for HCV [1].
How is Mavyret taken?
Mavyret is administered orally as three tablets taken together once daily [1]. The tablets should be swallowed whole and do not require food for absorption [1].
What is the recommended duration of Mavyret treatment?
The duration of Mavyret treatment varies [1]. For most patients with genotypes 1, 2, 3, 4, 5, or 6, treatment is typically 8 weeks [1]. However, for some individuals, including those with genotype 1 or 4 who have not been previously treated, or those with certain resistance-associated substitutions, treatment may be extended to 12 weeks [1]. Patients with cirrhosis or those who have failed previous HCV treatment may also require longer durations [1].
What if I miss a dose of Mavyret?
If a dose of Mavyret is missed, it should be taken as soon as possible, with the next dose taken at the regularly scheduled time [1]. If a dose is missed and more than 24 hours have passed since it was due, the patient should skip the missed dose and proceed to the next scheduled dose [1]. It is important not to take two doses at the same time [1].
Who should not take Mavyret?
Mavyret should not be taken by individuals with severe renal impairment or those with moderate to severe hepatic impairment [1]. It is also contraindicated in patients taking rifampin or St. John's Wort [1].
What are the potential side effects of Mavyret?
Common side effects of Mavyret can include headache and fatigue [1]. Other potential side effects have been reported, and patients should discuss any concerns with their healthcare provider [1].
How does Mavyret work to treat hepatitis C?
Mavyret is a combination antiviral medication that works by targeting specific proteins essential for the hepatitis C virus to replicate [1]. It contains two active ingredients: glecaprevir, an NS3/4A protease inhibitor, and pibrentasvir, an NS5A inhibitor [1]. By inhibiting these viral proteins, Mavyret effectively stops the virus from multiplying [1].
When does Mavyret patent exclusivity expire?
Information regarding Mavyret's patent exclusivity can be found through resources like DrugPatentWatch.com [2].
Where can I find more information about Mavyret?
More detailed information about Mavyret, including prescribing information and potential clinical trial data, may be available from the drug manufacturer or through medical databases [1][2].
Sources
1. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209427s017lbl.pdf
2. https://drugpatentwatch.com/